(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

BOSAYA

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

BOSAYA

ST13

US500000098535396

Class

5

Filing

98535396

Registration

8286329

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

31

Latest update

06/02/2026

Trademark type

Word

Nice classes

5

Filing date

05/06/2024

Registration date

06/02/2026

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

06/02/2026

Last transaction

06/02/2026

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use

First use anywhere

01/05/2026

First use in commerce

01/05/2026

Drawing code

4

Owner type

99

Owner location

Bengaluru, Karnataka, IN

Examiner

THOMAS, JULIE

Law office

L70

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

Biocon Biologics Limited

Representatives

Bentley J. Olive Olive Law Group, PLLC

Technical classification

Nice Classes

Class 5

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Pharmaceuticalmedical and biological preparations for treatment of osteoporosis in postmenopausal women; pharmaceuticalmedical and biological preparations for increasing bone mass in men with osteoporosis; pharmaceuticalmedical and biological preparations for treatment of glucocorticoid-induced osteoporosis; pharmaceuticalmedical and biological preparations for treatment of bone loss in men receiving androgen deprivation therapy for prostate cancer; pharmaceuticalmedical and biological preparations for treatment of bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer

Publications

History of USPTO decisions and trademark events.

31 publications found

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

06/02/2026

R.PR

REGISTERED-PRINCIPAL REGISTER

06/02/2026

SUNA

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

05/14/2026

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

05/14/2026

SUPC

STATEMENT OF USE PROCESSING COMPLETE

04/21/2026

IUAF

USE AMENDMENT FILED

04/16/2026

EISU

TEAS STATEMENT OF USE RECEIVED

04/16/2026

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

10/24/2025

EX2G

SOU EXTENSION 2 GRANTED

10/24/2025

AITU

CASE ASSIGNED TO INTENT TO USE PARALEGAL

10/24/2025

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

09/15/2025

EXT2

SOU EXTENSION 2 FILED

05/30/2025

EEXT

SOU TEAS EXTENSION RECEIVED

05/30/2025

EX1G

SOU EXTENSION 1 GRANTED

05/30/2025

EXT1

SOU EXTENSION 1 FILED

05/30/2025

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

12/31/2024

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

11/19/2024

PUBO

PUBLISHED FOR OPPOSITION

11/19/2024

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

11/13/2024

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

10/07/2024

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

09/03/2024

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

09/03/2024

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

09/03/2024

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

08/31/2024

GNRT

NON-FINAL ACTION E-MAILED

08/31/2024

CNRT

NON-FINAL ACTION WRITTEN

08/31/2024

DOCK

ASSIGNED TO EXAMINER

08/31/2024

TAEA

TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED

05/07/2024

PARI

TEAS VOLUNTARY AMENDMENT RECEIVED

05/07/2024

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

05/06/2024

NWAP

NEW APPLICATION ENTERED

05/06/2024

Continuous trademark protection

Get notified about every new filing that threatens BOSAYA or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.